London: Merck said on Thursday that its therapy has not met the main target disease free survival in some patients endometrial cancer during a final stage testing,

pharmaceutical manufacturer Keytruda Therapy in combination with Chemotherapy was being evaluated in patients with high risk endometrial cancer after surgery.

Other main goals of the study overall survival Not formally tested because the trial failed to show significant disease-free survival.

Endometrial cancer begins internal fibers The most common type of disease affecting the uterus, or endometrium, and the organ.

(Reporting by Christy Santosh in Bengaluru; Editing by Shaunak Dasgupta and Shilpi Majumdar)